They concluded that “if phosphorylation at different sites, or sets of sites, were to affect the RyR differently, this could explain how phosphorylating and dephosphorylating agents could both lead to enhanced activity.” Increased PP1 abundance could therefore possibly contribute to destabilized RyR both in CHF and MI. This evidence concerns the gene RYR2 and myocardial infarction.